Anti-HER2 (Margetuximab), Chimeric Antibody

Anti-HER2 (Margetuximab), Chimeric Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a chimeric IgG1 monoclonal antibody targeted against HER2/ERBB2. The original monoclonal antibody is derived from the parent antibody (Trastuzumab). Both antibodies bind efficiently to the same epitope of HER2 and mediate similar effects on cancer cells. However, in contrast to Trastuzumab, the Fc region of this monoclonal antibody is modified to increase the binding to CD16A and reduced binding to CD32B. Increased binding to CD16A leads to increased antibody-dependent cellular cytotoxicity (ADCC). The monoclonal antibody binds to the extracellular domain of HER2 expressed on tumor cells, inhibits tumor growth, and promotes ADCC. The original antibody received FDA approval to treat patients with metastatic HER2 cancer either alone or in combination with chemotherapy

Immunogen Sequence:Human HER2

Target Alternative Name:NEU, NGL, HER2, TKR1, CD340, HER-2, MLN 19; HER-2/neu, ERBB2, EC 2.7.10.1, Herstatin, P185erbB2, EC 2.7.10, MLN19

Species Reactivities:Human

Tag Line:The biosimilar is a chimeric monoclonal antibody that targets HER2

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.